Filtered By:
Drug: Folic Acid

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 203 results found since Jan 2013.

The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial
Background: Homocysteine has been postulated as a novel, potentially reversible risk factor for osteoporosis and related fractures. We evaluated whether homocysteine-lowering therapy with B-vitamins in patients with symptomatic cerebrovascular disease reduced the incidence of osteoporotic fractures. Methods: VITAmins To Prevent Stroke (VITATOPS) was a prospective randomised double-blind placebo-controlled trial in which 8,164 patients with recent (within 7 months) stroke or transient ischemic attack were randomly allocated to double-blind treatment with one tablet daily of either placebo (n = 4,075) or B-vitamins (folic ac...
Source: BMC Geriatrics - September 3, 2013 Category: Geriatrics Authors: John GommansQilong YiJohn EikelboomGraeme HankeyChristopher ChenHelen Rodgers Source Type: research

MTHFR C677T genotype and cardiovascular risk in a general population without mandatory folic acid fortification
Conclusions Our results do not support a causal relationship between homocysteine and CVD. However, we cannot exclude a direct causal effect of MTHFR C677T genotype on IHD.
Source: European Journal of Nutrition - September 25, 2014 Category: Nutrition Source Type: research

Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials Epidemiology
BackgroundResults from observational and genetic epidemiological studies suggest that lower serum homocysteine levels are associated with lower incidence of cardiovascular disease (CVD). Numerous randomized controlled trials have investigated the efficacy of lowering homocysteine with folic acid supplementation for CVD risk, but conflicting results have been reported.Methods and ResultsThree bibliographic databases (Medline, Embase, and the Cochrane Database of Systematic Reviews) were searched from database inception until December 1, 2015. Of the 1933 references reviewed for eligibility, 30 randomized controlled trials i...
Source: JAHA:Journal of the American Heart Association - August 14, 2016 Category: Cardiology Authors: Li, Y., Huang, T., Zheng, Y., Muka, T., Troup, J., Hu, F. B. Tags: Cardiovascular Disease, Diet and Nutrition Original Research Source Type: research

Medical cost savings in Sakado City and worldwide achieved by preventing disease by folic acid fortification.
Abstract The introduction of mandatory fortification of grains with folate in 1998 in the United States resulted in 767 fewer spina bifida cases annually and a cost savings of $603 million per year. However, far more significant medical cost savings result from preventing common diseases, including myocardial infarction, stroke, dementia and osteoporosis. A cost‐effectiveness analysis showed a gain of 266,649 quality‐adjusted life‐years and $3.6 billion saved annually, mainly due to the reduction of cardiac infarction. The recommended folate intake in Japan is 240 µg//d whereas it is 400 µg//d internationally. ...
Source: Congenital Anomalies - December 31, 2016 Category: Genetics & Stem Cells Authors: Yasuo Kagawa, Mami Hiraoka, Mitsuyo Kageyama, Yoshiko Kontai, Mayumi Yurimoto, Chiharu Nishijima, Kaori Sakamoto Tags: Invited Review Article Source Type: research

Folic acid therapy reduces the risk of mortality associated with heavy proteinuria among hypertensive patients
Objective: We aimed to evaluate whether proteinuria and estimated glomerular filtration rate (eGFR) levels can modify the efficacy of folic acid therapy on the risk of all-cause mortality among hypertensive patients in the China Stroke Primary Prevention Trial, a randomized, double-blind, and controlled trial. Methods: A total of 20 702 hypertensive patients without a history of major cardiovascular diseases were randomly assigned to a double-blind daily treatment of a single tablet containing 10-mg enalapril and 0.8-mg folic acid (n = 10 348), or 10-mg enalapril alone (n = 10 354). All-cause mortality, a pr...
Source: Journal of Hypertension - April 26, 2017 Category: Cardiology Tags: ORIGINAL PAPERS: Kidney Source Type: research

Folic acid reduces doxorubicin ‐induced cardiomyopathy by modulating endothelial nitric oxide synthase
Abstract The use of doxorubicin (DOXO) as a chemotherapeutic drug has been hampered by cardiotoxicity leading to cardiomyopathy and heart failure. Folic acid (FA) is a modulator of endothelial nitric oxide (NO) synthase (eNOS), which in turn is an important player in diseases associated with NO insufficiency or NOS dysregulation, such as pressure overload and myocardial infarction. However, the role of FA in DOXO‐induced cardiomyopathy is poorly understood. The aim of this study was to test the hypothesis that FA prevents DOXO‐induced cardiomyopathy by modulating eNOS and mitochondrial structure and function. Male C57B...
Source: Journal of Cellular and Molecular Medicine - June 13, 2017 Category: Molecular Biology Authors: Yanti Octavia, Georgios Kararigas, Martine Boer, Ihsan Chrifi, Rinrada Kietadisorn, Melissa Swinnen, Hans Duimel, Fons K. Verheyen, Maarten M. Brandt, Daniela Fliegner, Caroline Cheng, Stefan Janssens, Dirk J. Duncker, An L. Moens Tags: Original Article Source Type: research

Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.
Abstract The use of doxorubicin (DOXO) as a chemotherapeutic drug has been hampered by cardiotoxicity leading to cardiomyopathy and heart failure. Folic acid (FA) is a modulator of endothelial nitric oxide (NO) synthase (eNOS), which in turn is an important player in diseases associated with NO insufficiency or NOS dysregulation, such as pressure overload and myocardial infarction. However, the role of FA in DOXO-induced cardiomyopathy is poorly understood. The aim of this study was to test the hypothesis that FA prevents DOXO-induced cardiomyopathy by modulating eNOS and mitochondrial structure and function. Male...
Source: J Cell Mol Med - June 13, 2017 Category: Molecular Biology Authors: Octavia Y, Kararigas G, de Boer M, Chrifi I, Kietadisorn R, Swinnen M, Duimel H, Verheyen FK, Brandt MM, Fliegner D, Cheng C, Janssens S, Duncker DJ, Moens AL Tags: J Cell Mol Med Source Type: research

Folic acid deficiency enhanced microglial immune response via the Notch1/nuclear factor kappa B p65 pathway in hippocampus following rat brain I/R injury and BV2 cells.
Abstract Recent studies revealed that folic acid deficiency (FD) increased the likelihood of stroke and aggravated brain injury after focal cerebral ischaemia. The microglia-mediated inflammatory response plays a crucial role in the complicated pathologies that lead to ischaemic brain injury. However, whether FD is involved in the activation of microglia and the neuroinflammation after experimental stroke and the underlying mechanism is still unclear. The aim of the present study was to assess whether FD modulates the Notch1/nuclear factor kappa B (NF-κB) pathway and enhances microglial immune response in a rat m...
Source: J Cell Mol Med - May 12, 2019 Category: Molecular Biology Authors: Cheng M, Yang L, Dong Z, Wang M, Sun Y, Liu H, Wang X, Sai N, Huang G, Zhang X Tags: J Cell Mol Med Source Type: research

Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment
The objective of this study is to explore the current literature supporting the use oral multivitamins and multi/minerals (OMVMs) for cardiovascular diseases (CVD) treatment and prevention.Recent FindingsData on multivitamins, vitamin C and D, coenzyme Q, calcium, and selenium, has showed no consistent benefit for the prevention of CVD, myocardial infarction, or stroke, nor was there a benefit for all-cause mortality to support their routine supplementation. Folic acid alone and B vitamins with folic acid, B6 and B12, reduce stroke, whereas niacin and antioxidants are associated with an increased risk of all-cause mortalit...
Source: Current Cardiology Reports - February 13, 2020 Category: Cardiology Source Type: research

Preliminary analysis of immunoregulatory mechanism of hyperhomocysteinemia-induced brain injury in Wistar-Kyoto rats
In conclusion, the present study indicated that HHcy can promote inflammation by triggering Treg/Th17 immune imbalance to ameliorate the brain tissue damage.PMID:33790992 | PMC:PMC8005698 | DOI:10.3892/etm.2021.9914
Source: Experimental and Therapeutic Medicine - April 1, 2021 Category: General Medicine Authors: Yu Zhang Lin Wang Xin Li Jie Geng Source Type: research

Clinical profile and role of C-reactive protein and lactate dehydrogenase as prognostic marker and comparative efficacy of different pharmacotherapeutic agents in patients with cerebrovascular accident: An observational study
Dibya Jyoti Sharma, K Jeenaleima Singha, Karuna Das, Chandrama Das, M RakeshIndian Journal of Pharmacology 2021 53(6):484-488 The current study was conducted to determine the role of C-reactive protein (CRP) and lactate dehydrogenase (LDH) as prognostic-marker and outcomes of different pharmacotherapeutic agents among patients with cerebrovascular accident (CVA). A hospital-based observational study was conducted and patients with CVA admitted were included. Serum-CRP on admission correlated positively with modified Rankin score (mRS) (r = 0.9, P < 0.001) in ischemic stroke, whereas no correlation be...
Source: Indian Journal of Pharmacology - December 30, 2021 Category: Drugs & Pharmacology Authors: Dibya Jyoti Sharma K Jeenaleima Singha Karuna Das Chandrama Das M Rakesh Source Type: research

Health maintenance in women.
Abstract The health maintenance examination is an opportunity to focus on disease prevention and health promotion. The patient history should include screening for tobacco use, alcohol misuse, intimate partner violence, and depression. Premenopausal women should receive preconception counseling and contraception as needed, and all women planning or capable of pregnancy should take 400 to 800 mcg of folic acid per day. High-risk sexually active women should be counseled on reducing the risk of sexually transmitted infections, and screened for chlamydia, gonorrhea, and syphilis. All women should be screened for huma...
Source: American Family Physician - January 1, 2013 Category: Primary Care Authors: Riley M, Dobson M, Jones E, Kirst N Tags: Am Fam Physician Source Type: research

Homocysteine and migraine. A narrative review.
This article is hence aimed to provide an overview of epidemiological evidence about the association between homocysteine and migraine published in cross-sectional, prospective or interventional studies. Overall, the evidence gathered from cross-sectional studies that measured plasma homocysteine levels suggests that the epidemiological link between the plasma concentration of this biomarker and migraine is very weak, at best. Contradictory evidence emerged from interventional studies, in which treatment of hyperhomocysteinemia with folic acid or vitamin B supplementation was effective to lower plasma homocysteine and decr...
Source: International Journal of Clinical Chemistry - March 5, 2014 Category: Chemistry Authors: Lippi G, Mattiuzzi C, Meschi T, Cervellin G, Borghi L Tags: Clin Chim Acta Source Type: research

Hyperhomocysteinemia as a risk factor for the neuronal system disorders.
We present here an overview of recent data on the homocysteine metabolism and on the genetic and the metabolic causes of hyperhomocysteinemia-related pathologies in humans. In context of our results which detected an increased oxidative stress in hyperhomocysteinemic rats we discuss here the role of free radicals in this disorder. Imbalance between homocysteine auto-oxidation, production of reactive metabolites and cellular antioxidant defence induced by hyperhomocysteinemia results to cytotoxicity by oxidizing membrane lipids and proteins. Consequently, protein thiolation and homocysteinylation results in the structural a...
Source: J Physiol Pharmacol - February 1, 2014 Category: Drugs & Pharmacology Authors: Petras M, Tatarkova Z, Kovalska M, Mokra D, Dobrota D, Lehotsky J, Drgova A Tags: J Physiol Pharmacol Source Type: research